|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:activities
|
modulation of neurotransmitter release
|
|
gptkbp:analysis
|
ongoing
|
|
gptkbp:analyzes
|
gptkb:Dr._Smith
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:class
|
gptkb:Cloud_Computing_Service
|
|
gptkbp:clinical_trial
|
gptkb:Allergan
2 years
high
pending
Phase 2
Phase 3
NC T01234567
|
|
gptkbp:collaborations
|
gptkb:University_of_XYZ
international
ongoing
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:developed_by
|
gptkb:Allergan
|
|
gptkbp:field_of_study
|
pharmacology
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
gptkbp:frequency
|
once daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0717
|
|
gptkbp:indication
|
chronic pain
|
|
gptkbp:ingredients
|
C20 H24 N2 O2
|
|
gptkbp:invention
|
2035
patented
|
|
gptkbp:investment
|
high
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
treatment of pain
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:located_in
|
gptkb:USA
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
not yet marketed
|
|
gptkbp:participants
|
quality of life improvement
pain reduction
|
|
gptkbp:products
|
IN D123456
|
|
gptkbp:publishes
|
published
|
|
gptkbp:receives_funding_from
|
secured
|
|
gptkbp:regulatory_compliance
|
not approved
|
|
gptkbp:related_to
|
neuropathic pain
|
|
gptkbp:research
|
completed
planned
|
|
gptkbp:research_areas
|
pain management
|
|
gptkbp:safety_features
|
ongoing
acceptable
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
insomnia
dry mouth
|
|
gptkbp:status
|
ongoing
|
|
gptkbp:student_enrollment
|
200 patients
|
|
gptkbp:target_audience
|
adults
|
|
gptkbp:targets
|
gptkb:Nicotinic_acetylcholine_receptor
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:weight
|
324.42 g/mol
|
|
gptkbp:year_created
|
gptkb:2015
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:bfsLayer
|
4
|